Authors: Bressler B,Sands BE,
Address: Gastrointestinal Unit and MGH Crohn's and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Journal: Aliment Pharmacol Ther.

Publication: 2006 Nov 1;24(9):1283-93.

abstract

BACKGROUND:

Fistulae will develop in approximately one-third of patients with Crohn's disease. With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a Medical and possible surgical approach.

AIM:

To summarize the current literature evaluating various medical options for treating patients with fistulizing Crohn's disease.

METHODS:

A literature Review was conducted using PubMed (search terms: Crohn's disease and fistula) and manual search of references among the identified studies and relevant review papers to identify papers that present data on medical treatment of fistulizing Crohn's disease.

RESULTS:

The first line of medical therapy remains antibiotics (metronidazole and ciprofloxacin). Mercaptopurine and azathioprine are medications that are effective in treating fistulizing Crohn's disease. The current gold standard of medical treatment to induce and maintain remission for fistulizing Crohn's disease is infliximab. Used as induction therapy, infliximab produced a 62% clinical response, and a complete closure rate of 46%. A maintenance therapy trial demonstrated at 54 weeks, 46% of patients receiving infliximab continued to respond to treatment, compared with 23% in the placebo group (P = 0.001).

CONCLUSION:

Further research to find new therapies and to improve our existing medical treatment of fistulizing Crohn's disease is required.

Related Articles
Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.
Dig Dis Sci. 2009
Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.
Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Dig Dis Sci. 2009 Aug; 54(8):1746-52. Epub 2008 Nov 12.
Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Am J Gastroenterol. 2003
Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Am J Gastroenterol. 2003 Mar; 98(3):608-12.
Review Treatment of fistulizing Crohn's disease.
Gastroenterology. 2000
Review Treatment of fistulizing Crohn's disease.
Lichtenstein GR. Gastroenterology. 2000 Oct; 119(4):1132-47.
Review Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Cochrane Database Syst Rev. 2008
Review Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW, Bickston SJ. Cochrane Database Syst Rev. 2008 Jan 23; (1):CD006893. Epub 2008 Jan 23.
Fistula response to methotrexate in Crohn's disease: a case series.
Aliment Pharmacol Ther. 2003
Fistula response to methotrexate in Crohn's disease: a case series.
Mahadevan U, Marion JF, Present DH. Aliment Pharmacol Ther. 2003 Nov 15; 18(10):1003-8.
Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease.
J Allergy (Cairo). 2012
Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease.
Molendijk I, Duijvestein M, van der Meulen-de Jong AE, van Deen WK, Swets M, Hommes DW, Verspaget HW. J Allergy (Cairo). 2012; 2012:187408. Epub 2012 Sep 20.
Enterocutaneous fistula: medical and surgical management including patients with Crohn's disease.
Clin Colon Rectal Surg. 2010
Enterocutaneous fistula: medical and surgical management including patients with Crohn's disease.
Orangio GR. Clin Colon Rectal Surg. 2010 Sep; 23(3):169-75.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster